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Background
In virologically suppressed patients, switching to DRV/r
monotherapy maintains HIV RNA suppression, and
could also lower treatment costs.
Methods
In the MONET trial 256 patients with HIV RNA <50
copies/mL on current HAART for over 24 weeks
(NNRTI based (43%), or PI based (57%)), switched to
DRV/r 800/100 mg once daily, either as monotherapy
(n=127) or with 2NRTI (n=129). The Spanish costs per
patient with HIV RNA below 50 copies/mL were calcu-
lated, using a “switch included” analysis at Week 96, to
account for additional antiretrovirals taken after initial
treatment failure. Published prices were used.
Results
In the ITT switch included analysis, HIV RNA <50
copies/mL by Week 96 was 92.1% versus 90.7% in the
DRV/r monotherapy and control arms. No patients in
either arm developed phenotypic resistance to DRV.
Before the trial, the mean annual cost of antiretrovirals
was €4612 for patients on NNRTI based HAART, and
€9217 for patients on PI based HAART. During the
MONET trial, the mean annual per-patient cost of anti-
retrovirals was €9915 in the triple therapy arm, of which
45% was from NRTIs and 55% from PIs. The mean per-
patient cost in the monotherapy arm was €5915, a sav-
ing of 40%. We estimated 65,000 people treated with
antiretrovirals in Spain (50% NNRTI based, 50% PI
based) and 15% of patients (9,750) eligible for PI mono-
therapy. A switch to DRV/r monotherapy could cut the
two-year cost of antiretroviral treatment for these
patients, from €137 million to €115 million, a saving of
€22 million over two years.
Conclusions
Based on the MONET results, the lower cost of DRV/r
monotherapy versus triple therapy in Spain would allow
more patients to be treated for a fixed budget, or a sav-
ing of up to €22 million over two years, if all eligible
patients were switched, while maintaining HIV RNA
suppression below 50 copies/mL.
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